17TH WORKSHOP OF THE INTERNATIONAL ISOTOPE SOCIETY - CENTRAL EUROPEAN DIVISION. THE SYNTHESIS AND APPLICATIONS OF ISOTOPES AND ISOTOPICALLY LABELLED COMPOUNDS

摘要

Novel targeted MI-PET-tracers are discovered either by conventional drug design processes, i.e. Structure Activity Relationship (SAR) on existing therapeutic compound libraries or literature based scaffolds or using modem tools like combinatorial chemistry and high throughput screening. In a second step, the identified best candidates are investigated for a suitable radiolabelling position. A tailored radiosynthesis process is mandatory, due to the generally short radioactive half-lifes of the radioisotopes of choice, i.e. t_(1/2[F-18]) = 110 min. This short half-life is responsible for a relatively low radiation burden to the patients. However, the short half-life implicitly requires a fully automated radiosynthesis, which is a remote controlled production process, thus, ensuring reliable daily tracer production and distribution to the customer. Therefore, disposable cassette based production processes are developed and established.The low mass dose applied with MI-tracers (<100mug) allows for a fast development process and early 'proof of mechanism' (PoM) studies in patients via a so called 'micro-dose concept' initiated by the regulatory bodies. Data received from these PoM studies can be fed back into the compound generation and early development circle to facilitate further optimization and fine-tuning of the tracer candidates.BSP is actively working on unmet medical needs in various fields, especially in Oncology Imaging (i.e. prostate cancer, and highly tumor specific probes), CNS Imaging (i.e. early detection of dementia), and Cardiovascular Imaging (i.e. myocardial perfusion).Furthermore, Diagnostic Imaging is actively involved in the development of therapeutic drug projects in Oncology, Cardiology, and CNS indications by providing appropriate MI-PET tracers for patient selection and early therapy response monitoring. We actively partner with other pharmaceutical companies and academia to implement Ml as a valuable routine tool for personalized medicine and drug development.